Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 329

1.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.

Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M.

Eur Urol Focus. 2019 Sep 5. pii: S2405-4569(19)30270-6. doi: 10.1016/j.euf.2019.08.012. [Epub ahead of print]

PMID:
31495759
2.

Feasibility and accuracy of SPECT myocardial perfusion imaging in end-stage lung disease.

Schiopu SRI, Zacherl M, Todica A, Bartenstein P, Milger K, Leuschner G, Munker D, Bauer M, Massberg S, Behr J, Neurohr C, Huber BC, Kneidinger N.

J Nucl Cardiol. 2019 Aug 19. doi: 10.1007/s12350-019-01851-4. [Epub ahead of print]

PMID:
31428982
3.

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P.

J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472-6. doi: 10.1016/j.jhep.2019.08.006. [Epub ahead of print]

PMID:
31421157
4.

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.

Gosewisch A, Ilhan H, Tattenberg S, Mairani A, Parodi K, Brosch J, Kaiser L, Gildehaus FJ, Todica A, Ziegler S, Bartenstein P, Böning G.

EJNMMI Res. 2019 Aug 14;9(1):76. doi: 10.1186/s13550-019-0548-z.

5.

Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, Bartenstein P, Knösel T, Spitzweg C, Ilhan H, Todica A.

Eur J Nucl Med Mol Imaging. 2019 Aug 13. doi: 10.1007/s00259-019-04456-8. [Epub ahead of print]

PMID:
31410542
6.

Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET.

Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, Albert NL.

Eur J Nucl Med Mol Imaging. 2019 Aug 13. doi: 10.1007/s00259-019-04477-3. [Epub ahead of print]

PMID:
31410540
7.

Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.

Beyer L, Schnabel J, Kazmierczak P, Ewers M, Schönecker S, Prix C, Meyer-Wilmes J, Unterrainer M, Catak C, Pogarell O, Perneczky R, Albert NL, Bartenstein P, Danek A, Buerger K, Levin J, Rominger A, Brendel M.

Neuroimage Clin. 2019 Jul 22;24:101949. doi: 10.1016/j.nicl.2019.101949. [Epub ahead of print]

8.

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.

Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A, Griesinger C, Zwergal A, Levin J, Bartenstein P, Yakushev I, Cumming P, Boening G, Ziegler S, Herms J, Giese A, Rominger A.

Alzheimers Res Ther. 2019 Aug 1;11(1):67. doi: 10.1186/s13195-019-0522-z.

9.

Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.

Fleischmann DF, Unterrainer M, Corradini S, Rottler M, Förster S, la Fougère C, Siepmann T, Schwaiger M, Bartenstein P, Belka C, Albert NL, Niyazi M.

PLoS One. 2019 Jul 24;14(7):e0216111. doi: 10.1371/journal.pone.0216111. eCollection 2019.

10.

Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second Generation Amyloid-beta Mouse Model.

Sacher C, Blume T, Beyer L, Peters F, Eckenweber F, Sgobio C, Deussing M, Albert NL, Unterrainer M, Lindner S, Gildehaus FJ, von Ungern-Sternberg B, Brzak I, Neumann U, Saito T, Saido TC, Bartenstein P, Rominger A, Herms J, Brendel M.

J Nucl Med. 2019 Jul 13. pii: jnumed.119.227322. doi: 10.2967/jnumed.119.227322. [Epub ahead of print]

PMID:
31302633
11.

Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism.

Götzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J, Diehl-Schmid J, Levin J, Fellerer K, Reifschneider A, Bultmann S, Bartenstein P, Rominger A, Tahirovic S, Smith ST, Madore C, Butovsky O, Capell A, Haass C.

EMBO Mol Med. 2019 Jun;11(6). pii: e9711. doi: 10.15252/emmm.201809711.

12.

Teaching NeuroImages: Advanced imaging of neurosarcoidosis with 68Ga-DOTATATE PET/CT.

Unterrainer M, Ruf V, Ilhan H, Vettermann F, Holzgreve A, Cyran CC, Tonn JC, Bartenstein P, Albert NL.

Neurology. 2019 May 21;92(21):e2512-e2513. doi: 10.1212/WNL.0000000000007544. No abstract available.

PMID:
31110154
13.

Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET - Clinical relevance in glioma patients.

Galldiks N, Unterrainer M, Judov N, Stoffels G, Rapp M, Lohmann P, Vettermann F, Dunkl V, Suchorska B, Tonn JC, Kreth FW, Fink GR, Bartenstein P, Langen KJ, Albert NL.

Neuro Oncol. 2019 May 11. pii: noz083. doi: 10.1093/neuonc/noz083. [Epub ahead of print]

PMID:
31077276
14.

First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.

Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy JP, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR, Wängler C, Wängler B, Bartenstein P, Bernard-Gauthier V, Schirrmacher R.

ACS Chem Neurosci. 2019 Jun 19;10(6):2697-2702. doi: 10.1021/acschemneuro.9b00144. Epub 2019 Apr 29.

PMID:
31017386
15.

Ginkgo biloba Extract EGb 761 Improves Vestibular Compensation and Modulates Cerebral Vestibular Networks in the Rat.

Lindner M, Gosewisch A, Eilles E, Branner C, Krämer A, Oos R, Wolf E, Ziegler S, Bartenstein P, Brandt T, Dieterich M, Zwergal A.

Front Neurol. 2019 Feb 25;10:147. doi: 10.3389/fneur.2019.00147. eCollection 2019.

16.

68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases.

Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, Bartenstein P, Tonn JC, Albert NL.

Clin Nucl Med. 2019 May;44(5):412-413. doi: 10.1097/RLU.0000000000002513.

PMID:
30829858
17.

In response to: The validity of 18F-GE180 as a TSPO imaging agent.

Albert NL, Unterrainer M, Brendel M, Kaiser L, Zweckstetter M, Cumming P, Bartenstein P.

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1208-1211. doi: 10.1007/s00259-019-04294-8. Epub 2019 Mar 2. No abstract available.

PMID:
30826897
18.

[Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM)].

Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, Drzezga A, la Fougère C, Gründer G, Grünwald F, Krause BJ, Kuwert T, Langen KJ, Rominger A, Sabri O, Schreckenberger M, Meyer PT.

Nuklearmedizin. 2019 Feb;58(1):5-16. doi: 10.1055/a-0807-8137. Epub 2019 Feb 15. German.

PMID:
30769368
19.

FDG-PET in a Case of Very Late-onset Huntington's Disease.

Feil K, Brendel M, Hensler M, Bartenstein P, Seelos K, Dieterich M, Rominger A, Danek A.

Mov Disord Clin Pract. 2018 Mar 23;5(2):227-228. doi: 10.1002/mdc3.12601. eCollection 2018 Mar-Apr. No abstract available.

20.

Expression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models.

Nack A, Brendel M, Nedelcu J, Daerr M, Nyamoya S, Beyer C, Focke C, Deussing M, Hoornaert C, Ponsaerts P, Schmitz C, Bartenstein P, Rominger A, Kipp M.

Cells. 2019 Jan 28;8(2). pii: E94. doi: 10.3390/cells8020094.

Supplemental Content

Loading ...
Support Center